101 related articles for article (PubMed ID: 26091846)
1. Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2).
Onoda N; Sugitani I; Higashiyama T; Hara H; Ito K; Kammori M; Sugino K; Suzuki S; Toda K; Yoshida A; Miyauchi A
BMC Cancer; 2015 Jun; 15():475. PubMed ID: 26091846
[TBL] [Abstract][Full Text] [Related]
2. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.
Sugitani I; Onoda N; Ito KI; Suzuki S
J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641
[TBL] [Abstract][Full Text] [Related]
3. The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study.
Onoda N; Sugino K; Higashiyama T; Kammori M; Toda K; Ito K; Yoshida A; Suganuma N; Nakashima N; Suzuki S; Tsukahara K; Noguchi H; Koizumi M; Nemoto T; Hara H; Miyauchi A; Sugitani I
Thyroid; 2016 Sep; 26(9):1293-9. PubMed ID: 27484330
[TBL] [Abstract][Full Text] [Related]
4. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
[TBL] [Abstract][Full Text] [Related]
5. [The anaplastic thyroid carcinoma research consortium of Japan].
Sugitani I
Nihon Geka Gakkai Zasshi; 2012 Jul; 113(4):368-72. PubMed ID: 22928442
[TBL] [Abstract][Full Text] [Related]
6. Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.
Arora S; Christos P; Pham A; Desai P; Wernicke AG; Nori D; Chao KS; Parashar B
J Cancer Res Ther; 2014; 10(3):526-30. PubMed ID: 25313732
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic thyroid carcinoma: a 25-year single-institution experience.
Mohebati A; Dilorenzo M; Palmer F; Patel SG; Pfister D; Lee N; Tuttle RM; Shaha AR; Shah JP; Ganly I
Ann Surg Oncol; 2014 May; 21(5):1665-70. PubMed ID: 24554064
[TBL] [Abstract][Full Text] [Related]
9. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
von Roemeling CA; Copland JA
Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
Ladoire S; Rambach L; Quipourt V; Favier L; Ghiringhelli F; Arnould L; Pfitzenmeyer P; Fumoleau P; Coudert B
Clin Breast Cancer; 2011 Aug; 11(4):235-40. PubMed ID: 21737355
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
[TBL] [Abstract][Full Text] [Related]
12. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic thyroid cancer: a case report of a long term survival patient and review of literature data.
Ursino S; Fiorica F; Stefanelli A; Pedriali M; Colosimo C; Cocuzza P; Mazzotti V; Taibi R; Cartei F; Greco C
Eur Rev Med Pharmacol Sci; 2014; 18(9):1368-72. PubMed ID: 24867515
[TBL] [Abstract][Full Text] [Related]
14. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
16. Histopathological analysis of anaplastic thyroid carcinoma cases with long-term survival: A report from the Anaplastic Thyroid Carcinoma Research Consortium of Japan.
Hirokawa M; Sugitani I; Kakudo K; Sakamoto A; Higashiyama T; Sugino K; Toda K; Ogasawara S; Yoshimoto S; Hasegawa Y; Imai T; Onoda N; Orita Y; Kammori M; Fujimori K; Yamada H
Endocr J; 2016 May; 63(5):441-7. PubMed ID: 26842589
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
18. Fosbretabulin for the treatment of anaplastic thyroid cancer.
Granata R; Locati LD; Licitra L
Future Oncol; 2014 Oct; 10(13):2015-21. PubMed ID: 25396774
[TBL] [Abstract][Full Text] [Related]
19. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.
Levy A; Leboulleux S; Lepoutre-Lussey C; Baudin E; Ghuzlan AA; Hartl D; Deutsch E; Deandreis D; Lumbroso J; Tao Y; Schlumberger M; Blanchard P
Oral Oncol; 2015 Apr; 51(4):370-5. PubMed ID: 25595614
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma.
Akaishi J; Sugino K; Kitagawa W; Nagahama M; Kameyama K; Shimizu K; Ito K; Ito K
Thyroid; 2011 Nov; 21(11):1183-9. PubMed ID: 21936674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
